NCT02628132View on ClinicalTrials.gov

Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

December 31, 2019

Study Completion Date

March 24, 2020

Conditions
Breast Cancer
Interventions
DRUG

Paclitaxel

Paclitaxel will be given weekly for 6 cycles

DRUG

Durvalumab

Durvalumab will be given q2 wks concurrently with paclitaxel.

Trial Locations (1)

11211

King Faisal Specialist Hospital and Research Center, Riyadh

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

King Faisal Specialist Hospital & Research Center

OTHER